Attacking the genome: Emerging siRNA nanocarriers from concept to clinic

Current Opinion in Pharmacology

Volumn 12, Issue 4, 2012, Pages 427-433

  Alabi, Christopher ^a,b   Vegas, Arturo ^a,d   Anderson, Daniel ^a,b,c,d  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALN PCS02; ALN TTR01; ALN TTR02; ALN VSP; AMINOALCOHOL; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; APOLIPOPROTEIN B; ATU 027; C12 200; KINESIN; KINESIN SPINDLE PROTEIN; NANOCARRIER; NANOPARTICLE; POLO LIKE KINASE 1; POLYMER; PREALBUMIN; PROPROTEIN CONVERTASE SUBTILISN KEXIN TYPE 9; PROTEIN INHIBITOR; SERINE PROTEINASE; SMALL INTERFERING RNA; STABLE NUCLEIC ACID LIPID PARTICLE; SURVIVIN; TKM 08031; TKM APOLIPOPROTEIN B; TKM EBOLA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ADVANCED CANCER; AMYLOIDOSIS; BLADDER CANCER; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONJUGATE; DISEASE MODEL; DRUG MEGADOSE; DRUG TARGETING; EBOLA VIRUS; FLU LIKE SYNDROME; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; GENOME; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; LIPOSOMAL GENE DELIVERY SYSTEM; LIVER CELL CARCINOMA; LOW DRUG DOSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; SOLID TUMOR;

ANIMALS; GENE TRANSFER TECHNIQUES; GENOME; HUMANS; LIPIDS; NANOPARTICLES; POLYMERS; RNA, SMALL INTERFERING;

EID: 84864976211     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.05.004     Document Type: Review

References (42)

1. A. Fire, S. Xu, M.K. Montgomery, S.A. Kostas, S.E. Driver, and C.C. Mello Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans Nature 391 1998 806 811
2. K. Quon, and P.D. Kassner RNA interference screening for the discovery of oncology targets Expert Opin Ther Targets 13 2009 1027 1035
3. R.E. Tiedemann, Y.X. Zhu, J. Schmidt, H. Yin, C.X. Shi, Q. Que, G. Basu, D. Azorsa, L.M. Perkins, and E. Braggio Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6 Blood 115 2010 1594 1604
4. L.M. Murrow, S.V. Garimella, T.L. Jones, N.J. Caplen, and S. Lipkowitz Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome Breast Cancer Res Treat 122 2010 347 357
5. V. Goidts, J. Bageritz, L. Puccio, S. Nakata, M. Zapatka, S. Barbus, G. Toedt, B. Campos, A. Korshunov, and S. Momma RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival Oncogene 31 2012 3235 3243 10.1038/onc.2011.490
6. D.O. Azorsa, I.M. Gonzales, G.D. Basu, A. Choudhary, S. Arora, K.M. Bisanz, J.A. Kiefer, M.C. Henderson, J.M. Trent, and D.D. Hoff Von Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer J Transl Med 7 2009 43
7. A.D. Judge, V. Sood, J.R. Shaw, D. Fang, K. McClintock, and I. MacLachlan Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA Nat Biotechnol 23 2005 457 462
8. A.D. Judge, G. Bola, A.C.H. Lee, and I. MacLachlan Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo Mol Ther 13 2006 494 505
9. G.R. Rettig, and M.A. Behlke Progress toward in vivo use of siRNAs-II Mol Ther 20 2012 483 512 10.1038/mt.2011.263
10. T.W. Geisbert, A.C.H. Lee, M. Robbins, J.B. Geisbert, A.N. Honko, V. Sood, J.C. Johnson, S. de Jong, I. Tavakoli, and A. Judge Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study Lancet 375 2010 1896 1905
11. A.D. Judge, M. Robbins, I. Tavakoli, J. Levi, L. Hu, A. Fronda, E. Ambegia, K. McClintock, and I. MacLachlan Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice J Clin Invest 119 2009 661 673
12. S.C. Semple, A. Akinc, J. Chen, A.P. Sandhu, B.L. Mui, C.K. Cho, D.W.Y. Sah, D. Stebbing, E.J. Crosley, and E. Yaworski Rational design of cationic lipids for siRNA delivery Nat Biotechnol 28 2010 172 176
13. T. Zimmermann, A. Lee, A. Akinc, B. Bramlage, D. Bumcrot, M. Fedoruk, J. Harborth, J. Heyes, L. Jeffs, and M. John RNAi-mediated gene silencing in non-human primates Nature 441 2006 111 114
14. E. Ambegia, S. Ansell, P. Cullis, J. Heyes, L. Palmer, and I. MacLachlan Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression Biochim Biophys Acta 1669 2005 155 163
15. J.J. Wheeler, L. Palmer, M. Ossanlou, I. MacLachlan, R.W. Graham, Y.P. Zhang, M.J. Hope, P. Scherrer, and P.R. Cullis Stabilized plasmid-lipid particles: construction and characterization Gene Ther 6 1999 271 281
16. J. Heyes, L. Palmer, K. Bremner, and I. MacLachlan Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids J Control Release 107 2005 276 287
17. D. Morrissey, J. Lockridge, L. Shaw, K. Blanchard, K. Jensen, W. Breen, K. Hartsough, L. Machemer, S. Radka, and V. Jadhav Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs Nat Biotechnol 23 2005 1002 1007
18. A. Akinc, W. Querbes, S. De, J. Qin, M. Frank-Kamenetsky, K.N. Jayaprakash, M. Jayaraman, K.G. Rajeev, W.L. Cantley, and J.R. Dorkin Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms Mol Ther 18 2010 1357 1364
19. K.T. Love, K.P. Mahon, C.G. Levins, K.A. Whitehead, W. Querbes, J.R. Dorkin, J. Qin, W. Cantley, L.L. Qin, and T. Racie Lipid-like materials for low-dose, in vivo gene silencing Proc Natl Acad Sci USA 107 2010 1864 1869
20. K.J. Polach, M. Matar, J. Rice, G. Slobodkin, J. Sparks, R. Congo, A. Rea-Ramsey, D. McClure, E. Brunhoeber, and M. Krampert Delivery of siRNA to the mouse lung via a functionalized lipopolyamine Mol Ther 20 2012 91 100
21. J.C. Burnett, J.J. Rossi, and K. Tiemann Current progress of siRNA/shRNA therapeutics in clinical trials Biotechnol J 6 2011 1130 1146
22. L. Li, R. Wang, D. Wilcox, X. Zhao, J. Song, X. Lin, W.M. Kohlbrenner, S.W. Fesik, and Y. Shen Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery Gene Ther 19 2012 775 780 10.1038/gt.2011.146
23. S. Seth, Y. Matsui, K. Fosnaugh, Y. Liu, N. Vaish, R. Adami, P. Harvie, R. Johns, G. Severson, and T. Brown RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer Mol Ther 19 2011 928 935
24. F. Leuschner, P. Dutta, R. Gorbatov, T.I. Novobrantseva, J.S. Donahoe, G. Courties, K.M. Lee, J.I. Kim, J.F. Markmann, and B. Marinelli Therapeutic siRNA silencing in inflammatory monocytes in mice Nat Biotechnol 29 2011 1005 1010
25. T.I. Novobrantseva, A. Borodovsky, J. Wong, B. Klebanov, M. Zafari, K. Yucius, W. Querbes, P. Ge, V.M. Ruda, and S. Milstein Systemic RNAi-mediated gene silencing in nonhuman primate and rodent myeloid cells Mol Ther Nucleic Acids 1 2012 e4
26. A. Santel, M. Aleku, O. Keil, J. Endruschat, V. Esche, G. Fisch, S. Dames, K. Loeffler, M. Fechtner, and W. Arnold A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium Gene Ther 13 2006 1222 1234
27. A. Santel, M. Aleku, O. Keil, J. Endruschat, V. Esche, B. Durieux, K.L.O. ffler, M. Fechtner, T.R.O. hl, and G. Fisch RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy Gene Ther 13 2006 1360 1370
28. M. Aleku, P. Schulz, O. Keil, A. Santel, U. Schaeper, B. Dieckhoff, O. Janke, J. Endruschat, B. Durieux, and N. Roeder Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression Cancer Res 68 2008 9788 9798
29. K.A. Whitehead, G. Sahay, G.Z. Li, K.T. Love, C.A. Alabi, M. Ma, C. Zurenko, W. Querbes, R.S. Langer, and D.G. Anderson Synergistic silencing: combinations of lipid-like materials for efficacious siRNA delivery Mol Ther 19 2011 1688 1694 10.1038/mt.2011.141
30. O.M. Merkel, D. Librizzi, A. Pfestroff, T. Schurrat, K. Buyens, N.N. Sanders, S.C. De Smedt, M. Béhé, and T. Kissel Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging J Control Release 138 2009 148 159
31. H. Gonzalez, S.J. Hwang, and M.E. Davis New class of polymers for the delivery of macromolecular therapeutics Bioconjug Chem 10 1999 1068 1074
32. S.M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells Nature 411 2001 494 498
33. R.P. Kulkarni, S. Mishra, S.E. Fraser, and M.E. Davis Single cell kinetics of intracellular, nonviral, nucleic acid delivery vehicle acidification and trafficking Bioconjug Chem 16 2005 986 994
34. S. Mishra, J.D. Heidel, P. Webster, and M.E. Davis Imidazole groups on a linear, cyclodextrin-containing polycation produce enhanced gene delivery via multiple processes J Control Release 116 2006 179 191
35. D.W. Bartlett, and M.E. Davis Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles Bioconjug Chem 18 2007 456 468
36. S. Hu-Lieskovan, J.D. Heidel, D.W. Bartlett, M.E. Davis, and T.J. Triche Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma Cancer Res 65 2005 8984 8992
37. D.W. Bartlett, H. Su, I.J. Hildebrandt, W.A. Weber, and M.E. Davis Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging Proc Natl Acad Sci USA 104 2007 15549 15554
38. D.W. Bartlett, and M.E. Davis Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles Biotechnol Bioeng 99 2008 975 985
39. M.E. Davis, J.E. Zuckerman, C.H.J. Choi, D. Seligson, A. Tolcher, C.A. Alabi, Y. Yen, J.D. Heidel, and A. Ribas Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Nature 464 2010 1067 1070
40. D.B. Rozema, D.L. Lewis, D.H. Wakefield, S.C. Wong, J.J. Klein, P.L. Roesch, S.L. Bertin, T.W. Reppen, Q. Chu, and A.V. Blokhin Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes Proc Natl Acad Sci USA 104 2007 12982 12987
41. J.H. Jeong, H. Mok, Y.-K. Oh, and T.G. Park siRNA conjugate delivery systems Bioconjug Chem 20 2009 5 14
42. C. Troiber, and E. Wagner Nucleic Acid carriers based on precise polymer conjugates Bioconjug Chem 22 2011 1737 1752